Therapeutic Response

PD-L1 >= 1% status confers therapeutic sensitivity to Carboplatin in combination with Gemcitabine and Nivolumab in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy - 21 day. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved gemcitabine (1000mg/m^2) in combination with carboplatin (AUC 5) (21 day) and nivolumab for reimbursement as a treatment option for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1% (3 cycles only). The regimen further states that this combination is available in NCIS (00849.2).
Nivolumab 360mg and Chemotherapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of adult patients with resectable non-small cell lung cancer at high risk of recurrence whose tumors have PD-L1 expression >= 1%. The treatment regimen contians five treatment schedules: (1) nivolumab 360 mg, CARBOplatin (AUC6), and PAClitaxel (200 mg/m^2); (2) nivolumab 360mg, gemcitabine (1000 mg/m^2), and CARBOplatin (AUC5); (3) nivolumab 360 mg, gemcitabine 1250 mg/m^2, and CISplatin 75 mg/m^2; (4) nivolumab 360 mg, PEMEtrexed, and CARBOplatin with folic acid or multivtamin containig 350-1000 micrograms of folic acid; and (5) nivolumab 360 mg, PEMEtrexed, and CISplatin along with folic acid or multivitamin containig 350-1000 mg of folic acid.